Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

JAMA

Volumn 284, Issue 12, 2000, Pages 1549-1558

  Bhatt, Deepak L ^a   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO; TIROFIBAN;

ARTICLE; BLEEDING; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; HEART MUSCLE ISCHEMIA; HUMAN; PRIORITY JOURNAL; THROMBOCYTE; THROMBUS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0034721399     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.284.12.1549     Document Type: Article

References (94)

1. Statistics
2. Distal embolization in acute coronary syndromes
3. Platelet activation in patients after an acute coronary syndrome
4. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction
5. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
6. Platelet GPIIb-IIIa blockers
7. Clinical outcomes: Of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
8. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease
9. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
10. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II
11. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
12. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina
13. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revacularization
14. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
15. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina
16. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
17. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
18. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
19. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis
20. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta-3 blockade with percutaneous coronary intervention
21. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization
22. Sustained suppression of ischemic complications of coronary intervention by platelet Gp IIb/IIIa blockade with abciximab
23. Complementary clinical benefits of coronary artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors
24. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting
25. Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention
26. The benefit of abciximab in interventional cardiology is not device-specific
27. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology
28. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions
29. Consistent and durable reduction in death and myocardial infarction with abciximab during coronary intervention in acute coronary syndromes and stable angina
30. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting
31. 'Rescue' utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty
32. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty
33. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients
34. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE)
35. Recognition of the importance of embolization in atherosclerotic vascular disease
36. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes
37. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels
38. Angiographic findings in patients with refractory unstable angina according to troponin T status
39. Eptifibatide reduces the size and incidence of myocardial infarction in patients with non-ST-elevation acute coronary syndromes
40. Maintenance of clinical benefit at six-months in patients treated with the platelet glycoprotein IIb/IIIa inhibitor eptifibatide versus placebo during an acute ischemic coronary event
41. Troponin concentrations for stratification cf patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban
42. Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000
43. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes
44. Coronary bypass surgery within 12 hours of administration of abciximab remains safe despite an increased risk of perioperative bleeding
45. Benefit of tirofiban + heparin therapy in unstable angina/non-Q-wave myocardial in farction patients is observed regardless of interventional treatment strategy
46. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes
47. Heparin use is required for clinical benefit of Gp IIb/IIIa inhibitor eptifibatide in acute coronary syndromes
48. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and beparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardial infarction
49. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction
50. The effect of glycoprotein IIb/IIIa inhibition on rebound ischemia following discontinuation of heparin therapy
51. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina
52. Evaluation of combination therapy with tirofiban and enoxaparin in patients with unstable angina and non-Q-wave myocardial infarction
53. Stroke in patients with acute coronary syndromes
54. Readministration of abciximab is as effective as first time administration with similar risks
55. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
56. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction
57. Assessment of the treatment effect of enoxapanin for unstable angina/non-Q-wave myocardial infarction
58. Long-term low-molecular-mass heparin in unstable coronary-artery disease
59. Evaluation of combination therapy with tirofiban and enoxaparin in patients with unstable angina and non-Q-wave myocardial infarction
60. Combination enoxaparin-abciximab therapy during coronary intervention
61. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention
62. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation
63. Clinical outcomes of bivalirudin for ischemic heart disease
64. Pharmacodynamics of a direct thrombin inhibitor combined with a GP IIb-IIIa antagonist
65. Unstable angina pectoris
66. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition
67. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody
68. Abciximab reduces death in diabetics following percutaneous coronary intervention
69. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
70. Costs and effects in therapy for acute coronary syndromes
71. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes
72. Improved cardiac outcomes in diabetic unstable angina/non-Q-wave myocardial infarction patients treated with tirofiban and heparin
73. The effect of GP IIb/IIIa antagonists in patients with diabetes: A meta-analysis
74. Bedside platelet monitoring
75. Rapid platelet-function assay
76. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects
77. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
78. Assessing the optimal level of platelet inhibition with GP IIb/IIIa inhibitors in patients undergoing coronary intervention
79. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization
80. Oral glycoprotein IIb/IIIa inhibition with Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial
81. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes
82. Increased mortality with oral glycoprotein IIb/IIIa antagonists
83. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes
84. Does earlier administration of eptifibatide reduce death and MI in patients with acute coronary syndromes?
85. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease
86. Enhanced efficacy of eptifibatide administration to patients with an acute coronary syndrome requiring in-hospital coronary artery bypass grafting
87. Routine platelet transfusion in patients undergoing emergency coronary by pass surgery after receiving abciximab
88. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery
89. Prior aspirin users are at increased risk of cardiac events and should be treated with enoxaparin
90. Prior aspirin use in unstable coronary syndromes results in a lower incidence of non-Q-wave MI but a higher rate of medical therapy failure with unfractionated heparin: The aspirin paradox
91. The prevalence of aspirin resistance in cardiac patients as measured by platelet aggregation and the PFA-100
92. Enhanced benefit of eptifibatide in patients with acute coronary syndromes using a seamless transition from community/hospitals to tertiary care centers
93. Prospective use of glycoprotein IIb/IIIa receptor blockers in the emergency department setting